Advertisement
Canada markets close in 2 hours 59 minutes

  • S&P/TSX

    22,040.24
    -228.88 (-1.03%)
     

  • S&P 500

    5,243.40
    -34.11 (-0.65%)
     

  • DOW

    38,285.19
    -401.13 (-1.04%)
     

  • CAD/USD

    0.7329
    -0.0010 (-0.13%)
     

  • CRUDE OIL

    74.15
    -2.84 (-3.69%)
     

  • Bitcoin CAD

    94,176.59
    +1,343.88 (+1.45%)
     

  • CMC Crypto 200

    1,485.59
    +17.65 (+1.20%)
     

  • GOLD FUTURES

    2,368.10
    +22.30 (+0.95%)
     

  • RUSSELL 2000

    2,054.10
    -16.02 (-0.77%)
     

  • 10-Yr Bond

    4.4060
    -0.1080 (-2.39%)
     

  • NASDAQ

    16,683.22
    -51.80 (-0.31%)
     

  • VOLATILITY

    13.94
    +1.02 (+7.89%)
     

  • FTSE

    8,262.75
    -12.63 (-0.15%)
     

  • NIKKEI 225

    38,923.03
    +435.13 (+1.13%)
     

  • CAD/EUR

    0.6731
    -0.0031 (-0.46%)
     
MARKETS LIVE BLOG:

STOCKS FALL BUT GAMESTOP SURGES ON REDDIT BET

ISM report shows further contraction in U.S. manufacturing activity

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks Equity Research
·2 min read

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike.

Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term.

Is This 1 Momentum Stock a Screaming Buy Right Now?

For momentum investors, upward or downward trends in a stock's price or earnings outlook take precedent, so they'll want to zero in on the Momentum Style Score. This Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

ADVERTISEMENT

Vertex Pharmaceuticals (VRTX)

Boston, MA-based Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company’s main area of focus is cystic fibrosis (CF).

VRTX is a Zacks Rank #3 (Hold) stock, with a Momentum Style Score of A and VGM Score of B. Shares are up 3.7% over the past one week and up 11.5% over the past four weeks. VRTX has gained 31.2% in the last one-year period as well. Looking at trading volume, an average of 1,089,863.25 shares exchanged hands over the last 20 trading days.

Momentum investors also pay close attention to a company's earnings. For VRTX, seven analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.22 to $17.14 per share for 2024. VRTX boasts an average earnings surprise of 5.9%.

Investors should take the time to consider VRTX for their portfolios due to its solid Zacks Ranks, notable earnings metrics, and impressive Momentum and VGM Style Scores.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research